21st Austria weekly - Marinomed 22/05/2024 [pic1]Marinomed: Biotech AG VSE:MARI announces revenues of EUR 0.7 million recorded in the first quarter 2024. After observing record from Carragelose product sales heavily influenced by SARS-CoV-2 pandemic over past years revenue 2024 has declined to levels observed before pandemic. This decline is mostly due high inventories and return seasonality causing a drop customer demand. Due cost-conscious cash management equivalents stood at 1.9 compared 2.6 end 2023. The operating result EBIT -1.9 Q1 2023: -1.4 million loss for period amounted -2.1 million. “Although we are making constant progress working on several initiatives parallel situation remains challenging. Revenues
EQS-News: Marinomed Biotech AG / Key word: Quarter Results
Marinomed Biotech AG announces results for the first quarter of 2024
22.05.2024 / 07:45 CET/CEST
The issuer.
21st Austria weekly - Marinomed Agrana A1 Telekom 16/04/2024 [pic1]Agrana: Fruit starch sugar company Agrana generated operating profit EBIT of € 151.0 million in its 2023|24 financial year 1 March 2023 to 29 February 2024 which is line with guidance a very significant improvement compared the prior 2022|23: 88.3 million. Earnings per share rose 1.04 prior year: 0.25. Consolidated revenue amounted 3 786.9 3 637.4 As previously communicated Q3 results published January 2024 sees itself confronted an increasingly challenging business environment since fourth quarter and forecasts EBIT for 2024|25 will be significantly below comparable figure 2023|24. This decline already become apparent first 2024|25.Agrana: performance: -0.74% Marinomed: Marinomed